Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Nov 27

PMID 34834183

Citations 10

Authors

Mustafa Erelel

Mert Kaskal

Ozlem Akbal-Dagistan

Halim Issever

Ahmet Serhan Dagistanli

Hilal Balkanci

Merve Sinem Oguz

Aygun Qarayeva

Meltem Culha

Aybige Erturk

Nur Sena Basarir

Gokben Sahin

Ali Yagiz Uresin

Ahmet Ogul Araman

Alpay Medetalibeyoglu

Tufan Tukek

Mustafa Oral Oncul

Ayca Yildiz-Pekoz

Affiliations

Soon will be listed here.

Abstract

In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the "Device Group"; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.

Citing Articles

The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.

Song Y, Wu Y, Ding F, Li S, Shen Y, Yang B Biomolecules. 2024; 14(9).

PMID: 39334845 PMC: 11430252. DOI: 10.3390/biom14091078.

Development and validation of risk prediction nomograms for acute respiratory failure in elderly patients with hip fracture.

Li Y, Dong B J Orthop Surg Res. 2023; 18(1):899.

PMID: 38007467 PMC: 10676597. DOI: 10.1186/s13018-023-04395-z.

Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review.

Gupta B, Ahluwalia P, Gupta N, Gupta A Indian J Crit Care Med. 2023; 27(8):572-579.

PMID: 37636853 PMC: 10452767. DOI: 10.5005/jp-journals-10071-24511.

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease.

Shute J Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111341 PMC: 10141002. DOI: 10.3390/ph16040584.

The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics.

Eilts F, Bauer S, Fraser K, Dordick J, Wolff M, Linhardt R Carbohydr Polym. 2023; 299:120167.

PMID: 36876764 PMC: 9516881. DOI: 10.1016/j.carbpol.2022.120167.

References

Yildiz-Pekoz A, Ozsoy Y . Inhaled Heparin: Therapeutic Efficacy and Recent Formulations. J Aerosol Med Pulm Drug Deliv. 2017; 30(3):143-156. DOI: 10.1089/jamp.2015.1273. View

Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D . Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem. 1997; 272(17):11313-20. DOI: 10.1074/jbc.272.17.11313. View

Tandon R, Sharp J, Zhang F, Pomin V, Ashpole N, Mitra D . Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol. 2020; 95(3). PMC: 7925120. DOI: 10.1128/JVI.01987-20. View

Ghezzi S, Cooper L, Rubio A, Pagani I, Capobianchi M, Ippolito G . Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res. 2017; 140:13-17. PMC: 7113768. DOI: 10.1016/j.antiviral.2016.12.023. View

Guan M, Zeng X, Shi R, Zheng Y, Fan W, Su W . Aerosolization Performance, Antitussive Effect and Local Toxicity of Naringenin-Hydroxypropyl-β-Cyclodextrin Inhalation Solution for Pulmonary Delivery. AAPS PharmSciTech. 2021; 22(1):20. DOI: 10.1208/s12249-020-01889-5. View

Navas-Blanco J, Dudaryk R . Management of Respiratory Distress Syndrome due to COVID-19 infection. BMC Anesthesiol. 2020; 20(1):177. PMC: 7369540. DOI: 10.1186/s12871-020-01095-7. View

Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A . Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis. 2004; 10(3):413-8. PMC: 3322807. DOI: 10.3201/eid1003.030683. View

Wang F, Zhang N, Li B, Liu L, Ding L, Wang Y . Heparin defends against the toxicity of circulating histones in sepsis. Front Biosci (Landmark Ed). 2015; 20(8):1259-70. DOI: 10.2741/4370. View

Matthay M, Thompson B, Ware L . The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?. Lancet Respir Med. 2021; 9(8):933-936. PMC: 8075801. DOI: 10.1016/S2213-2600(21)00105-3. View

10.

Billett H, Reyes-Gil M, Szymanski J, Ikemura K, Stahl L, Lo Y . Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thromb Haemost. 2020; 120(12):1691-1699. PMC: 7869055. DOI: 10.1055/s-0040-1720978. View

11.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-1099. PMC: 9906401. DOI: 10.1111/jth.14817. View

12.

Mishra G, Mulani J . Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med. 2020; 9(1):e8. PMC: 7836750. DOI: 10.1016/S2213-2600(20)30530-0. View

13.

Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G . Association Between Hypoxemia and Mortality in Patients With COVID-19. Mayo Clin Proc. 2020; 95(6):1138-1147. PMC: 7151468. DOI: 10.1016/j.mayocp.2020.04.006. View

14.

Tuinman P, Dixon B, Levi M, Juffermans N, Schultz M . Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations. Crit Care. 2012; 16(2):R70. PMC: 3681399. DOI: 10.1186/cc11325. View

15.

Maca J, Jor O, Holub M, Sklienka P, Bursa F, Burda M . Past and Present ARDS Mortality Rates: A Systematic Review. Respir Care. 2016; 62(1):113-122. DOI: 10.4187/respcare.04716. View

16.

Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G . Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011; 6(8):e23710. PMC: 3161750. DOI: 10.1371/journal.pone.0023710. View

17.

Young E . The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2007; 122(6):743-52. DOI: 10.1016/j.thromres.2006.10.026. View

18.

Labiris N, Dolovich M . Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003; 56(6):588-99. PMC: 1884307. DOI: 10.1046/j.1365-2125.2003.01892.x. View

19.

Hippensteel J, LaRiviere W, Colbert J, Langouet-Astrie C, Schmidt E . Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol. 2020; 319(2):L211-L217. PMC: 7381711. DOI: 10.1152/ajplung.00199.2020. View

20.

Dixon B, Smith R, Campbell D, Moran J, Doig G, Rechnitzer T . Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9(4):360-372. PMC: 7826120. DOI: 10.1016/S2213-2600(20)30470-7. View